These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 10070933)
1. Searching for evidence of altered gene expression: a comment on statistical analysis of microarray data. Wittes J; Friedman HP J Natl Cancer Inst; 1999 Mar; 91(5):400-1. PubMed ID: 10070933 [No Abstract] [Full Text] [Related]
2. Searching for the ideal SERM. Poletti A Pharmacol Res; 1999 May; 39(5):333. PubMed ID: 10328989 [No Abstract] [Full Text] [Related]
3. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Newby JC; Johnston SR; Smith IE; Dowsett M Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855 [TBL] [Abstract][Full Text] [Related]
4. In search of the perfect SERM: beyond tamoxifen and raloxifene. McNeil C J Natl Cancer Inst; 1998 Jul; 90(13):956-7. PubMed ID: 9665139 [No Abstract] [Full Text] [Related]
5. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. Hilsenbeck SG; Friedrichs WE; Schiff R; O'Connell P; Hansen RK; Osborne CK; Fuqua SA J Natl Cancer Inst; 1999 Mar; 91(5):453-9. PubMed ID: 10070945 [TBL] [Abstract][Full Text] [Related]
6. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. Lykkesfeldt AE; Madsen MW; Briand P Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264 [TBL] [Abstract][Full Text] [Related]
7. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro. Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399 [TBL] [Abstract][Full Text] [Related]
8. The regulation of estrogen receptor expression and function in human breast cancer. Ferguson AT; Lapidus RG; Davidson NE Cancer Treat Res; 1998; 94():255-78. PubMed ID: 9587692 [No Abstract] [Full Text] [Related]
9. Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. Arteaga CL; Koli KM; Dugger TC; Clarke R J Natl Cancer Inst; 1999 Jan; 91(1):46-53. PubMed ID: 9890169 [TBL] [Abstract][Full Text] [Related]
10. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. Brinkman A; van der Flier S; Kok EM; Dorssers LC J Natl Cancer Inst; 2000 Jan; 92(2):112-20. PubMed ID: 10639512 [TBL] [Abstract][Full Text] [Related]
11. Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling. Badia E; Duchesne MJ; Semlali A; Fuentes M; Giamarchi C; Richard-Foy H; Nicolas JC; Pons M Cancer Res; 2000 Aug; 60(15):4130-8. PubMed ID: 10945620 [TBL] [Abstract][Full Text] [Related]
12. Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer. Girault I; Bièche I; Lidereau R Maturitas; 2006 Jul; 54(4):342-51. PubMed ID: 16822624 [TBL] [Abstract][Full Text] [Related]
13. Antiestrogen therapy: uncertainties and risk assessment. Smith LL; White IN Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):14-22. PubMed ID: 9556786 [TBL] [Abstract][Full Text] [Related]
14. A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543 [TBL] [Abstract][Full Text] [Related]
15. The effect of ICI 164384 and beta-interferon on the growth and steroid receptor profile of breast cancer cell lines. Coradini D; Biffi A; Pirronello E; Di Fronzo G Anticancer Res; 1995; 15(6B):2557-61. PubMed ID: 8669823 [TBL] [Abstract][Full Text] [Related]
16. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121 [TBL] [Abstract][Full Text] [Related]
17. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976 [TBL] [Abstract][Full Text] [Related]
18. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809 [TBL] [Abstract][Full Text] [Related]
19. Presence of an insulin-like growth factor I autocrine loop predicts uterine fibroid responsiveness to tamoxifen. Howe SR; Pass HI; Ethier SP; Matthews WJ; Walker C Cancer Res; 1996 Sep; 56(17):4049-55. PubMed ID: 8752178 [TBL] [Abstract][Full Text] [Related]
20. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. van Agthoven T; Sieuwerts AM; Meijer D; Meijer-van Gelder ME; van Agthoven TL; Sarwari R; Sleijfer S; Foekens JA; Dorssers LC Endocr Relat Cancer; 2010 Mar; 17(1):215-30. PubMed ID: 19966015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]